Pfizer (PFE) Stock News: $44 Million Chantix Settlement Gets Final Approval

Judge Katherine Polk Failla granted final approval of Pfizer’s $44 million Chantix settlement on October 14, 2026, the day after the fairness hearing, and dismissed the claims against Pfizer with prejudice, according to OpenClassActions. There were no objections and one request for exclusion.

What the case alleged#

The multidistrict litigation (No. 22-MD-3050) claimed the stop-smoking drug Chantix (varenicline) contained an undisclosed nitrosamine impurity and that Pfizer misrepresented its adherence to manufacturing standards. Pfizer recalled Chantix in 2021. The company denies wrongdoing and settled to avoid the cost of continued litigation; the court did not decide the merits.

Claims and fees#

Settlement administrator A.B. Data reported 3,581,486 consumer claims and 17,885 third-party-payor claims as of September 28, none yet fully reviewed. The court awarded class counsel $14.67 million in fees, one-third of the fund, plus about $144,000 in expenses and service awards. The claim deadline was September 14, 2026; payments follow the effective date with no date announced.

Why it matters for the stock#

For readers following PFE, $44 million is immaterial to a company of Pfizer’s size and closes a five-year-old recall matter. The more useful reading is the claims volume: more than 3.5 million consumer claims on a $44 million fund means small individual payments, which is typical of consumer drug settlements and distinct from the personal-injury litigation that can carry far larger costs.

Read the full case page on OpenClassActions.

Published October 21, 2026. Informational reporting, not legal or investment advice. TickerPosts and OpenClassActions.com share a founder. Settlements resolve claims without an admission of wrongdoing, and allegations in pending lawsuits are unproven.